19 research outputs found
Overall survival according to P16 AQUA score.
<p>P16 AQUA score with a cutpoint at 244 in patients with pretreatment hemoglobin≥120 g/L.</p
Progression-free survival according to P16 AQUA score.
<p>P16 AQUA score with a cutpoint at 244 in patients with pretreatment hemoglobin≥120 g/L.</p
Univariate analysis: 5-year progression-free survival (PFS).
<p>ECOG PS: Eastern Cooperative Oncology Group Performance Status; RT: radiotherapy; CRT: chemoradiotherapy; Hb: hemoglobin; DAB: diaminobenzydene, CISH: chromogenic <i>in situ</i> hybridization</p><p>Univariate analysis: 5-year progression-free survival (PFS).</p
CISH for HPV16 and AQUA score correlation.
<p>CISH for HPV16 and AQUA score correlation.</p
P16 expression by AQUA according to HPV subtype.
<p>P16 expression by AQUA according to HPV subtype.</p
Characteristics of 89 patients with anal canal carcinoma.
<p>ECOG PS: Eastern Cooperative Oncology Group Performance Status; RT: radiotherapy.</p><p>Characteristics of 89 patients with anal canal carcinoma.</p
Histogram of AQUA scores with cutpoint identifying very high expression of p16.
<p>Histogram of AQUA scores with cutpoint identifying very high expression of p16.</p
Src and some of the signaling pathways downstream of Src.
<p>Src regulates several downstream signaling pathways including the STAT3 pathway, the PI3K pathway, and the MAPK pathway.</p
Src+STAT3 siRNA reduces tumor formation in NOD/SCID mice.
<p>1×10<sup>6</sup> cells transfected with control (mice 1–4) or Src+STAT3 siRNAs (mice 5–8) were implanted into the mammary fat pad of mice. After 66 days, the tumors were excised and weighed (significant differences are indicated (*; p<0.05)(<b>A</b>). Sections of the tumor were stained (<b>B</b>) or subjected to immunostaining with anti-GFP antibody (<b>C</b>). Malignant cells are indicated by an arrow. A portion of each tumor was homogenized with RIPA buffer and immunoblotted with anti-GFP antibodies (<b>D</b>).</p